QS-ORAL Trademark

Trademark Overview


On Friday, February 28, 2025, a trademark application was filed for QS-ORAL with the United States Patent and Trademark Office. The USPTO has given the QS-ORAL trademark a serial number of 99061621. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Monday, August 4, 2025. This trademark is owned by Q-VANT Biosciences, Inc.. The QS-ORAL trademark is filed in the Pharmaceutical Products category with the following description:

Oral vaccine preparations; Adjuvants for use with vaccines; Adjuvants for medical purposes; Human vaccine preparations; Vaccine adjuvants; Vaccine preparations; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical products for the prevention and treatment of cancer; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Plant extracts, other than essential oils,...
qs-oral

General Information


Serial Number99061621
Word MarkQS-ORAL
Filing DateFriday, February 28, 2025
Status641 - NON-FINAL ACTION - MAILED
Status DateMonday, August 4, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Pseudo MarkQSORAL
Goods and ServicesOral vaccine preparations; Adjuvants for use with vaccines; Adjuvants for medical purposes; Human vaccine preparations; Vaccine adjuvants; Vaccine preparations; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical products for the prevention and treatment of cancer; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Plant extracts, other than essential oils, for pharmaceutical purposes; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical products for the treatment of viral diseases
Pseudo MarkQS ORAL

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, February 28, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameQ-VANT Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressForestdale, MA 02644

Trademark Events


Event DateEvent Description
Friday, February 28, 2025NEW APPLICATION ENTERED
Friday, February 28, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, February 28, 2025APPLICATION FILING RECEIPT MAILED
Monday, August 4, 2025ASSIGNED TO EXAMINER
Monday, August 4, 2025NON-FINAL ACTION WRITTEN
Monday, August 4, 2025NON-FINAL ACTION E-MAILED
Monday, August 4, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED